Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 5:10:1088773.
doi: 10.3389/fped.2022.1088773. eCollection 2022.

Neurological manifestations of Kawasaki disease and multisystem inflammatory syndrome in children associated with COVID-19: A comparison of two different clinical entities

Affiliations
Review

Neurological manifestations of Kawasaki disease and multisystem inflammatory syndrome in children associated with COVID-19: A comparison of two different clinical entities

A Mauro et al. Front Pediatr. .

Abstract

Kawasaki disease (KD) is one of the most frequent idiopathic vasculitis in children, affecting medium- and small-sized vessels. Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 has recently emerged as a new systemic hyperinflammatory condition affecting children some weeks after an acute COVID-19 infection. KD and MIS-C share different aspects and differ in many others: patients affected by MIS-C are usually older, with prominent gastrointestinal manifestations, diffuse adenopathy, extensive conjunctivitis, myocardial damage, leukopenia, and thrombocytopenia at the laboratory exams. Both conditions can present neurological complications. The aim of this manuscript is to provide a narrative review of neurological involvement in KD and MIS-C. A comprehensive review literature has been performed, and the main clinical features have been analyzed, contributing to neurological differential diagnosis.

Keywords: COVID-19; Kawasaki disease; children; multisystem inflammatory disease; neurological involvement.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Singh S, Jindal AK, Pilania RK. Diagnosis of Kawasaki disease. Int J Rheum Dis. (2018) 21(1):36–44. 10.1111/1756-185X.13224 - DOI - PMC - PubMed
    1. Cimaz R, Fanti E, Mauro A, Voller F, Rusconi F. Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records. Eur J Pediatr. (2017) 176:1061–5. 10.1007/s00431-017-2947-3 - DOI - PubMed
    1. Wood LE, Tulloh RM. Kawasaki disease in children. Heart. (2009) 95(10):787–92. 10.1136/hrt.2008.143669 - DOI - PubMed
    1. Shreya A, Devendra KA. Kawasaki disease: etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol. (2017) 13:247–58. 10.1080/1744666X.2017.1232165 - DOI - PMC - PubMed
    1. Rife E, Gedalia A. Kawasaki disease: an update. Curr Rheumatol Rep. (2020) 22(10):75. 10.1007/s11926-020-00941-4 - DOI - PMC - PubMed

LinkOut - more resources